6-(propylamino)nicotinonitrile | 501378-37-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-(propylamino)nicotinonitrile
• 英文别名: 6-(Propylamino)-3-pyridinecarbonitrile；6-(propylamino)pyridine-3-carbonitrile
• CAS: 501378-37-6
• 化学式: C₉H₁₁N₃
• mdl: MFCD09928823
• 分子量: 161.206
• InChiKey: XNMRXDWXYSBGSN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  48.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-(propylamino)nicotinonitrile 在 sodium azide 、 zinc dibromide 作用下， 以 水 、 异丙醇 为溶剂， 反应 2.0h， 以0.036 g的产率得到N-propyl-5-(2H-tetrazol-5-yl)pyridin-2-amine
  参考文献：
  名称：

  3-Nitro-4-amino benzoic acids and 6-amino nicotinic acids are highly selective agonists of GPR109b

  摘要：

  A series of 3-nitro-4-substituted-aminobenzoic acids were prepared and found to act as potent and highly selective agonists of the orphan human GPCR GPR109b, a low affinity receptor for niacin. No activity was observed at the closely homologous high affinity niacin receptor, GPR109a. A second series, comprising 6-amino-substituted nicotinic acids was, also prepared and several analogues showed comparable activity to the nitroaryl series. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.09.058
• 作为产物：
  描述：

  正丙胺 、 6-氯-3-氰基吡啶 在 N,N-二异丙基乙胺 作用下， 以 异丙醇 为溶剂， 反应 2.0h， 生成 6-(propylamino)nicotinonitrile
  参考文献：
  名称：

  3-Nitro-4-amino benzoic acids and 6-amino nicotinic acids are highly selective agonists of GPR109b

  摘要：

  A series of 3-nitro-4-substituted-aminobenzoic acids were prepared and found to act as potent and highly selective agonists of the orphan human GPCR GPR109b, a low affinity receptor for niacin. No activity was observed at the closely homologous high affinity niacin receptor, GPR109a. A second series, comprising 6-amino-substituted nicotinic acids was, also prepared and several analogues showed comparable activity to the nitroaryl series. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.09.058

文献信息

• 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1424336A1

  公开（公告）日：2004-06-02

  This invention provides a compound represented by the formula (I) : wherein R1 is a hydrogen atom, a halogen atom, hydroxy, nitro, optionally halogenated alkyl, alkoxy optionally having substituents, acyl or amino optionally having substituents; R2 is pyridyl, furyl, thienyl, pyrrolyl, quinolyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, tetrahydroquinolyl or thiazolyl, each of which may have substituents; n is 1 or 2; or a salt. And this invention provides a safe pharmaceutical comprising the compound of the formula (I) , which has an excellent apoptosis inhibitory effect and MIF binding effect, for preventing and/or treating heart disease, nervous degenerative disease, cerebrovascular disease, central nervous infectious disease, traumatorathy, demyelinating disease, bone and articular disease, kidney disease, liver disease, osteomyelodysplasia, AIDS, cancer, and the like.

  这项发明提供了一种由以下式（I）表示的化合物： 其中R1是氢原子、卤素原子、羟基、硝基、可选择具有卤素取代基的烷基、可选择具有取代基的烷氧基、酰基或氨基； R2是吡啶基、呋喃基、噻吩基、吡咯基、喹啉基、吡嗪基、嘧啶基、吡啶并嘧啶基、吲哚基、四氢喹啉基或噻唑基，每种基团可能具有取代基； n为1或2；或其盐。该发明提供了一种安全的药物，包括具有优异的凋亡抑制作用和MIF结合作用的式（I）化合物，用于预防和/或治疗心脏病、神经退行性疾病、脑血管疾病、中枢神经感染性疾病、创伤病变、脱髓鞘疾病、骨骼和关节疾病、肾脏疾病、肝脏疾病、骨髓发育不良、艾滋病、癌症等。
• [EN] IMIDAZO '1,2-A' PYRAZINE COMPOUNDS WHICH INTERACT WITH PROTEIN KINASES<br/>[FR] COMPOSES DE 1,2-A' PYRAZINE IMIDAZO INTERAGISSANT AVEC LES PROTEINES KINASES
  申请人：BIOFOCUS DISCOVERY LTD

  公开号：WO2005085252A1

  公开（公告）日：2005-09-15

  The present invention relates to a novel compounds of formula I, to pharmaceutical compounds, to processes for their preparation, as well as to the use of the compounds in the inhibition of protein kinases, in particular serine/threonine kinases, more particularly mitogen activated protein kinase, more particularly the c-Jun NH2-teminal kinases (JNKs). The invention also relates to the compounds for use in medicine and particularly n the prevention and/or treatment of a wide variety of diseases including inflammatory disorders, cancer, angiogenesis, diabetes, metabolic disease and neurological disorders.

  本发明涉及一种式I的新型化合物，以及制备这些化合物的药物化合物的方法，以及化合物在抑制蛋白激酶中的应用，特别是丝氨酸/苏氨酸激酶，更具体地是丝氨酸/苏氨酸激酶，更具体地是c-Jun NH2-teminal激酶（JNKs）。该发明还涉及这些化合物在医学上的应用，特别是在预防和/或治疗包括炎症性疾病、癌症、血管生成、糖尿病、代谢性疾病和神经系统疾病在内的各种疾病中的应用。
• 1, 3-benzothiazinone derivatives and use thereof
  申请人：Kajino Masahiro

  公开号：US20050032786A1

  公开（公告）日：2005-02-10

  This invention provides a compound represented by the formula (I): wherein R 1 is a hydrogen atom, a halogen atom, hydroxy, nitro, optionally halogenated alkyl, alkoxy optionally having substituents, acyl or amino optionally having substituents; R 2 is pyridyl, furyl, thienyl, pyrrolyl, quinolyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, tetrahydroquinolyl or thiazolyl, each of which may have substituents; n is 1 or 2; or a salt. And this invention provides a safe pharmaceutical comprising the compound of the formula (I), which has an excellent apoptosis inhibitory effect and MIF binding effect, for preventing and/or treating heart disease, nervous degenerative disease, cerebrovascular disease, central nervous infectious disease, traumatorathy, demyelinating disease, bone and articular disease, kidney disease, liver disease, osteomyelodysplasia, AIDS, cancer, and the like.

  该发明提供了一个由式(I)表示的化合物：其中R1是氢原子、卤素原子、羟基、硝基、可选取代卤代烷基、可选取代基的烷氧基、酰基或氨基；R2是吡啶基、呋喃基、噻吩基、吡咯基、喹啉基、吡嗪基、嘧啶基、吡嗪啉基、吲哚基、四氢喹啉基或噻唑基，每个基团都可以有取代基；n为1或2；或其盐。该发明提供了一种安全的药物，包括式(I)化合物，具有出色的抑制细胞凋亡和结合MIF的效果，用于预防和/或治疗心脏病、神经退行性疾病、脑血管疾病、中枢神经感染性疾病、创伤性疾病、脱髓鞘疾病、骨骼和关节疾病、肾脏疾病、肝脏疾病、骨髓发育不良、艾滋病、癌症等疾病。
• C-4" POSITION SUBSTITUTED MACROLIDE DERIVATIVE
  申请人：Sugimoto Tomohiro

  公开号：US20140046043A1

  公开（公告）日：2014-02-13

  A macrolide compound represented by the formula (I) effective against erythromycin resistant bacteria (for example, resistant pneumococci, streptococci and mycoplasmas).

  一种大环内酯化合物，化学式为（I），对红霉素耐药的细菌有效（例如，耐药的肺炎球菌，链球菌和支原体）。
• US7399759B2
  申请人：——

  公开号：US7399759B2

  公开（公告）日：2008-07-15